{"name":"NervGen Pharma","slug":"nervgen-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgJBVV95cUxPYnJ0dmtvZ1laUE0zOWhHY3VWOXZpbTJWbFpIX0UwWDRfMC0tUHlGQVpnR1dReFctbzlaR3YtREJNQ3dTWlp1Q1Fwa09uaTd0UjZseDJidGoyN0hKZG54dkJaR1YyeW1zZm14SVB4ZmtTeUp4WWhZaUJzTzJyUWdEZkhjUWd2QnN4dFJVNDhoVTNqSm1nOGRJLWEyWm9QVl9oc0N1OWEyTTBiOXhKQmdQNDZ6eF9DSFVSMEp5Q3VSTFc1Q2ctLVdhRldacVlGWWQxQ1luX19zTGFWYkJMd0ppVFpJZ0gzY2xPejNQYUQ4QlJ5bFFNa1B6dTUxQWZ1c3lRZTFGSU0wN3ZsdE1oT0NndTdYTUIyaU5Ob0pILWdSb0Q4OG45Y1EzNGJrNFVnajl4Rm9RV0tsUjJWUjIxVXFEYzdtUUdOUQ?oc=5","date":"2026-04-07","type":"regulatory","source":"TradingView","summary":"Nervgen Pharma Announces Successful End-Of-Phase 2 Meeting And FDA Alignment On Restore, A Phase 3 Registrational Study Of Nvg-291 For Chronic Tetraplegia - TradingView","headline":"Nervgen Pharma Announces Successful End-Of-Phase 2 Meeting And FDA Alignment On Restore, A Phase 3 Registrational Study ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE5HemY1MW1GSkdua0FFR1BNX2tUODhBLXk5SXhpSTJTeDhyQjhjTDEyTjlrcE10a0pxZXNua1FLWEEtcTVjNUhfSm1qUEQ5TUY2aU4tb2Rlbks2OGVvampDcWt1a9IBY0FVX3lxTE5HemY1MW1GSkdua0FFR1BNX2tUODhBLXk5SXhpSTJTeDhyQjhjTDEyTjlrcE10a0pxZXNua1FLWEEtcTVjNUhfSm1qUEQ5TUY2aU4tb2Rlbks2OGVvampDcWt1aw?oc=5","date":"2026-04-07","type":"trial","source":"Bitget","summary":"NervGen Pharma Corp. announces that patient enrollment for its Phase 1B/2a CONNECT-SCI clinical trial targeting individuals with quadriplegia due to subacute spinal cord injury is nearing completion. ","headline":"NervGen Pharma Corp. announces that patient enrollment for its Phase 1B/2a CONNECT-SCI clinical trial targeting individu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNdUk0N1NucFlZRnZMNGFPOURadGhuOGFLYVlVb3pDMlZwbS1zaXZoRVRYcGFxLVZvOVRkNENablo1MHJETkdsTkJUdHo5MjhzOUhPZXMtdjJZcHdQdUFyaWg0ZUJxVFgwcTFXaDNvTEpZenoyLTR3cC10czBpQkVNZk5uTFV5Sk9IUGRsRFJhXzRMN0RYRHhYQ2RBbU11Y2EyZlg5R3lBSUNSay1VaTZPbGVfSEgzby1nU0lRMzduaVJqbnBaTE9HV1h2U2RFVE9TWllZUjB1azk4Q1pFZkxpNHJsa1J1T00?oc=5","date":"2026-04-07","type":"regulatory","source":"marketscreener.com","summary":"Nervgen Pharma announces successful end-of-phase 2 meeting and FDA alignment on Restore, a phase 3 registrational study of NVG-291 for chronic tetraplegia - marketscreener.com","headline":"Nervgen Pharma announces successful end-of-phase 2 meeting and FDA alignment on Restore, a phase 3 registrational study ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"regulatory","source":"The Manila Times","summary":"NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia - The Manila Times","headline":"NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOZTgwemduNGY2ZHRkLTBHWXhSWEFieHhOaDFENGI4LTk3ZWNzVnA2bENSSjVxbmhNalFnMldwcWRHeXptR08zTkZaUlpKWHZpQlotaE82Slc4ci1LcjBwa2wxWGVaNXJZVWNITzNyLTY1Rk1PdkI5QWt0bEFzZnB2Ums3V1pfSVRDd3o4WUN3TU5MaWpBbTRpeFgtX0dOMkxHNzNfTTI0ek4zVnNjcTdGdTVNdw?oc=5","date":"2026-04-06","type":"pipeline","source":"TipRanks","summary":"NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel - TipRanks","headline":"NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQNHV4ek9TR3cyUXVJcmtPckpDc2FpeTV5RGZSRkl0SnJVNnJuRTJrUVBWQVR3WkQ4V0NuRE9yYnN6OEtoYlg4YmFaN0ZaUUxXLUFhcW1yWTl3MkJCdFZKLWdRNlIzc0VGc1hVcjU4M19qbFJEc0NCbUVwSkJwOW1Vd1JIblRCV1hfd1BJV21kdmxfaTljUjl4WUlxZVpxSktWUlN3NTBLMnFIcFNNMzJr?oc=5","date":"2026-04-06","type":"deal","source":"富途牛牛","summary":"Maxim Group Initiates NervGen Pharma(NGEN.US) With Buy Rating, Announces Target Price $10 - 富途牛牛","headline":"Maxim Group Initiates NervGen Pharma(NGEN.US) With Buy Rating, Announces Target Price $10 - 富途牛牛","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPTE83c1pqeF9wMG84dWxTX0x5eU9yTEdCZU1KMEZzelN6RlZjSGVCeEN4QnlZVm1tU0xkbmpLOTV0SGNxMVZMLVE2YWFYNzBGMXBOU3Z3dWp1cnVJelFZTmpGa1lMbFZOZGJBVnZmc2lnUkVQLWNSNW5aOXQtUFczYkppN2FIbnMyMUpfdmh4NUJGekItcGJYRmxubHh6Rm4xWUxB?oc=5","date":"2026-03-31","type":"pipeline","source":"Yahoo Finance","summary":"NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates - Yahoo Finance","headline":"NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQUFdvTXhqUWY5eHJvV3FSSDNSRmN0T1pySzExQ0MyUXpLSFNQRDZhYlBWazhsVzhpYzdWc0hrS1NFYU15X0VLb2xpUld3U3J0MGtsYXpvcmYtMGN2TXN3d1o2WHZQS2RmSHg2WDNhZm1sUnVubXNGalBFOGlzdkd0dzRLMTRwTjI5eHdZR3J3bkRUcEx6OFNMc3pkZ2tacVZJU0RzQnJJRlpOcVZUcVVpRQ?oc=5","date":"2026-03-17","type":"pipeline","source":"Seeking Alpha","summary":"NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) (NASDAQ:NGEN) - Seeking Alpha","headline":"NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) (NASDAQ:NGEN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOaHIyaUpqSm02bHRzZGdtN2RxVHRZMGMtTHAtaHVoRFNFRnpqaUJpVldWbjY0LWxueWU4SXByYVhBZzlKWkYwQ3pfZ0tFM0xSeTZ6cXRtZGhSRzA5cVdiTDVSRkxZZXFZN21TeGJWcWx0bF9QclBfazhwR01Wc2NmTUppek9BS1JLTXZCSi1iak9SQTcxc2dxTHJkamM2eUZRR2cwdlRjdmFtRlNTZW4wZlVfTDZXN3ZUUDVDMkFicWM5OFNGaVdSNVl3QXdwOHFWUnJZRVlyNFlwdw?oc=5","date":"2026-03-12","type":"pipeline","source":"globenewswire.com","summary":"NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange - globenewswire.com","headline":"NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBIc1RUVHIydC01SjFuWWhkeWZ2T2VBakJEVkc2S1d6VVpRRDh2OExCZ19HUFBFTUszNGlfNDRBWWRsOVRWVWc0Qm9PZXE4RkF1U0p6QVJBUDFxZUU1SXZOSG5sTEhVZXdERjNOOFc4R0s?oc=5","date":"2026-01-22","type":"pipeline","source":"Nasdaq","summary":"NervGen Pharma Rings the Closing Bell - Nasdaq","headline":"NervGen Pharma Rings the Closing Bell","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPTU1tRDJrS3JGV1V4bGhMSkI2YmRINWJwMFdFc2VYc0htOXM1RnNSWllWUkdaTzk3a19rNFZOT3MyN3hYdDgzaEtMMnRyay1lX2dGT0RuMWJBeFNueWF3M2lDRnRGU3JSQ04yWE4wT3QyRHN5M3NZbk5aekJEbnhfV3llYi1nMzJFVlBaYm1QMV9TZlpJWHhLVmp3cU5aMUdoT0tjWm01bEpTbE9RQW9fc25ncWpic3U1dnpOZnIzbzdMVFZEM2lF?oc=5","date":"2025-11-24","type":"earnings","source":"TMX Newsfile","summary":"NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates - TMX Newsfile","headline":"NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQOFN2Zk1VNUJweUJlVEdaTzNiSmdPTGlDQ3BrOEhYS1FQYTRxWWJmb195SFBWWVF3YU56azdMclRkMzl5ZnUtdXNldFppNmhYdWNvYnRvaWtieW1vNHZlSERSaVAyNy1rWVkwWC12V2hqY1JQaTdEODFnbkNaOGNzNGVQWjZoQVR0RkNZWDBqLW14ek53ZU1KbU5fZ3VtRkxzdXdZTHBJeE5IdHVmQnNocQ?oc=5","date":"2025-06-14","type":"trial","source":"neurologylive.com","summary":"Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury - neurologylive.com","headline":"Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}